Heart FailureCONNECT-HFNCT03035474
Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure
A study testing Digital Engagement and Direct Engagement in people with Heart Failure, run by Duke University at 154 sites in United States.
Trial summary
CONNECT-HF is a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multifaceted, health system-level quality-improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure
- What is being tested?
- Digital Engagement and Direct Engagement
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5,749 participants
- Where
- 154 sitesUnited States
- Study dates
- 21 Apr 2017to 31 Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Acute HF as a primary cause of hospitalization
- Hospitalizations for acute HF will be determined by local clinician-investigators but should include the following:
- Symptoms (eg, dyspnea, fatigue), signs (eg, elevated jugular venous pressure, peripheral edema), or laboratory/imaging evidence of HF (eg, pulmonary congestion on chest x-ray, elevated natriuretic peptide levels) during the hospitalization and
- Treatments aimed at acute HF (eg, intravenous diuretics, vasodilators, or inotropes)
- LVEF ≤ 40% based on last local measurement using echocardiography, multigated acquisition scan, computed tomography (CT) scanning, magnetic resonance imaging, or ventricular angiography
- Planned discharge to home or other supported care facility where patients are individually responsible for medication management
Who cannot join
- Prior heart transplant or current/planned left ventricular assistance device
- Chronic kidney disease requiring dialysis
- Terminal illness other than HF, such as malignancy, or with a life expectancy of less than 1 year as determined by the enrolling clinician-investigator
- Unable to participate in longitudinal follow-up, such as plans to move outside the US in the following year
Trial locations and contacts
154 sites in 1 country.
154 sites in 1 country
United States154 sites
Summa Health
Akron, Ohio, 44304
Albany Medical Center Hospital
Albany, New York, 12208
St. Peter's Hospital
Albany, New York, 12208
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, 87131
Rapides Regional Medical Center
Alexandria, Louisiana, 71301
Inova Alexandria Hospital
Alexandria, Virginia, 22304
Providence Alaska Medical Center
Anchorage, Alaska, 99508
St. Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
Anne Arundel Medical Center
Annapolis, Maryland, 21401
King's Daughters Medical Center
Ashland, Kentucky, 41101
Piedmont Athens Regional Medical Center
Athens, Georgia, 30606
Grady Memorial Hospital
Atlanta, Georgia, 30303
JFK Medical Center
Atlantis, Florida, 33462
AU Medical Center
Augusta, Georgia, 30912
University of Colorado Hospital
Aurora, Colorado, 80045
Copley Memorial Hospital
Aurora, Illinois, 60504
Presence Mercy Medical Center
Aurora, Illinois, 60506
Texas Cardiac Arrhythmia Research Foundation
Austin, Texas, 78705
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
San Gorgonio Memorial Hospital
Banning, California, 92220
Suburban Hospital
Bethesda, Maryland, 20814
Billings Clinic Hospital
Billings, Montana, 59101
University of Alabama Hospital
Birmingham, Alabama, 35233
Indiana University Health Bloomington
Bloomington, Indiana, 47403
St. Mary's Medical Center
Blue Springs, Missouri, 64014
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Manatee Memorial Hospital
Bradenton, Florida, 34208
Blake Medical Center
Bradenton, Florida, 34209
Our Lady of Lourdes Medical Center
Camden, New Jersey, 08103
Charlotte-Mecklenburg Hospital Authority
Charlotte, North Carolina, 28203
John H. Stroger Jr. Hospital of Cook County
Chicago, Illinois, 60612
University of Illinois Hospital and Health Sciences System
Chicago, Illinois, 60612
MedStar Southern Maryland Hospital Center
Clinton, Maryland, 20735
UC Health Memorial
Colorado Springs, Colorado, 80909
Johns Hopkins University
Columbia, Maryland, 21044
Medical City Dallas Hospital
Dallas, Texas, 75230
Genesis Medical Center-Davenport
Davenport, Iowa, 52803
Miami Valley Hospital
Dayton, Ohio, 45409
Wayne State University
Detroit, Michigan, 48201
Henry Ford Health System
Detroit, Michigan, 48202
St. John Hospital and Medical Center
Detroit, Michigan, 48236
St Lukes Hospital
Duluth, Minnesota, 55805
Duke University Hospital
Durham, North Carolina, 27710
University Hospitals - Elyria Medical Center
Elyria, Ohio, 44035
Englewood Hospital and Medical Center
Englewood, New Jersey, 07631
Hurley Medical Center
Flint, Michigan, 48503
Broward Health Imperial Point
Fort Lauderdale, Florida, 33308
Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Sparks Regional Medical Center
Fort Smith, Arkansas, 72901
Plaza Medical Center of Fort Worth
Fort Worth, Texas, 76104
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Altru Health System
Grand Forks, North Dakota, 58201
Spectrum Health
Grand Rapids, Michigan, 49503
Northern Colorado Medical Center
Greeley, Colorado, 80631
Self Regional Healthcare
Greenwood, South Carolina, 29646
Memorial Hospital at Gulfport
Gulfport, Mississippi, 39502
The Queens Medical Center
Honolulu, Hawaii, 96813
Ben Taub General Hospital
Houston, Texas, 77030
Huntington Hospital
Huntington, New York, 11743
Cape Code Hospital
Hyannis, Massachusetts, 02601
Jackson-Madison County General Hospital
Jackson, Tennessee, 38301
Mayo Clinic Florida
Jacksonville, Florida, 32224
United Health Services Hospitals
Johnson City, New York, 13790
Memorial Medical Center
Johnstown, Pennsylvania, 15905
Glacier View Research Institute-Cardiology
Kalispell, Montana, 59901
St. Joseph Medical Center
Kansas City, Missouri, 64114
University of Tennessee Medical Center
Knoxville, Tennessee, 37920
Mayo Clinic Health System Franciscan Medical Center
La Crosse, Wisconsin, 54601
McLaren Greater Lansing
Lansing, Michigan, 48910
University Medical Center
Las Vegas, Nevada, 89102
WellSpan Good Samaritan Hospital
Lebanon, Pennsylvania, 17042
KentuckyOne Health - Saint Joseph Hospital
Lexington, Kentucky, 40504
Bryan Medical Center
Lincoln, Nebraska, 68506
Arkansas Heart Hospital and Clinics
Little Rock, Arkansas, 72211
Monmouth Medical Center
Long Branch, New Jersey, 07740
Christus Good Shepherd Medical Center
Longview, Texas, 75601
Norton Women and Children's Hospital
Louisville, Kentucky, 40205
Norton Brownsboro Hospital
Louisville, Kentucky, 40241
Duke Cardiology of Lumberton
Lumberton, North Carolina, 28358
Medical Center, Navicent Health (THE)
Macon, Georgia, 31201
St. John Macomb-Oakland
Madison Heights, Michigan, 48071
Baptist Health Madisonville
Madisonville, Kentucky, 42431
Baptist Memorial Hospital
Memphis, Tennessee, 38120
MidMichigan Medical Center Midland
Midland, Michigan, 48670
Ascension Columbia St. Mary's Hospital
Milwaukee, Wisconsin, 53211
Memorial Medical Center
Modesto, California, 95355
McLaren Macomb
Mount Clemens, Michigan, 48043
Indiana University Health Ball Memorial Hospital
Muncie, Indiana, 47303
Southern NH Medical Center
Nashua, New Hampshire, 03060
Centennial Medical Center
Nashville, Tennessee, 37203
Natchitoches Regional Medical Center
Natchitoches, Louisiana, 71457
Jersey Shore University Medical Center
Neptune City, New Jersey, 07753
Ochsner Medical Center
New Orleans, Louisiana, 70121
Mount Sinai Beth Israel
New York, New York, 10003
Saint Michael's Medical Center
Newark, New Jersey, 07102
Riverside Regional Medical Center
Newport News, Virginia, 23601
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
North Kansas City Hospital
North Kansas City, Missouri, 64116
Oklahoma University Health Science Center
Oklahoma City, Oklahoma, 73104
Integris Baptist Medical Center
Oklahoma City, Oklahoma, 73112
Specialty Physicians of Illinois
Olympia Fields, Illinois, 60461
Orlando Health
Orlando, Florida, 32806
Cardiovascular Institute of Northwest Florida
Panama City, Florida, 32401
Baptist Hospital
Pensacola, Florida, 32501
Sacred Heart Hospital
Pensacola, Florida, 32504
McLaren - Northern Michigan
Petoskey, Michigan, 49770
The Heart Hospital Baylor Plano
Plano, Texas, 75093
AtlantiCare Regional Medical Center
Pomona, New Jersey, 08240
OHSU Hospital and Clinics
Portland, Oregon, 97239
Ascension-All Saints
Racine, Wisconsin, 53405
Duke Raleigh Hospital
Raleigh, North Carolina, 27609
WakeMed
Raleigh, North Carolina, 27610
Dignity Health Sequoia Hospital
Redwood City, California, 94062
Reid Health
Richmond, Indiana, 47374
CJW Medical Center
Richmond, Virginia, 23235
Valley Hospital
Ridgewood, New Jersey, 07450
Riverside Community Hospital
Riverside, California, 92501
Saint Anthony Medical Center
Rockford, Illinois, 61108
Adventist HealthCare Shady Grove
Rockville, Maryland, 20850
Sutter Medical Center
Sacramento, California, 95816
Lakeland Hospital
Saint Joseph, Michigan, 49085
Methodist Hospital
San Antonio, Texas, 78229
Sarasota Memorial Hospital
Sarasota, Florida, 34239
Ellis Hospital
Schenectady, New York, 12309
Harborview Medical Center
Seattle, Washington, 98104
Guadalupe Regional Medical Center
Seguin, Texas, 78155
Louisiana State University-Health Science Center- Shreveport
Shreveport, Louisiana, 71103
Robert Wood Johnson University Hospital Somerset
Somerville, New Jersey, 08876
South Miami Hospital
South Miami, Florida, 33143
St Johns Hospital
Springfield, Illinois, 62702
Cox Medical Centers
Springfield, Missouri, 65807
Springfield Regional Medical Center
Springfield, Ohio, 45504
Bayfront Health - St. Petersburg
St. Petersburg, Florida, 33701
Northside Hospital
St. Petersburg, Florida, 33709
Stamford Hospital
Stamford, Connecticut, 06904
Stanford University
Stanford, California, 94305
Staten Island University Hospital
Staten Island, New York, 10305
Richmond University Medical Center
Staten Island, New York, 10310
University Hospital (Stony Brook)
Stony Brook, New York, 11794
St. Joseph's Hospital
Syracuse, New York, 13203
Florida Hospital Tampa
Tampa, Florida, 33613
St. Joseph's Hospital
Tampa, Florida, 33614
Holy Name Medical Center
Teaneck, New Jersey, 07666
Montefiore Medical Center
The Bronx, New York, 10467
Torrance Memorial Medical Center
Torrance, California, 90505
University of Texas Health Science Center at Tyler
Tyler, Texas, 75708
The Carle Foundation Hospital
Urbana, Illinois, 61801
St. John Macomb Hospital
Warren, Michigan, 48093
Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188
Wheeling Hospital
Wheeling, West Virginia, 26003
New Hanover Regional Medical Center
Wilmington, North Carolina, 28402
Novant Health Forsyth Medical Center
Winston-Salem, North Carolina, 27103
Winter Haven Hospital
Winter Haven, Florida, 33881
About this study
Official title: Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure (CONNECT-HF)
CONNECT-HF is a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multifaceted, health system-level quality-improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics.
Read the detailed description
This trial will be a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multifaceted, health system-level quality-improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics. Outcomes will be assessed following discharge for participants hospitalized with acute HF and reduced left ventricular ejection fraction. All participants in the trial will be consented for follow-up as part of the CONNECT-HF registry on clinical outcomes, medication use, and participant-centered outcomes, including quality-of-life (QOL) assessments will be collected up to 12 months post-discharge at pre-specified intervals (6 weeks and 3, 6, and 12 months).
The health-system QI program will involve site visits and ongoing mentoring from teams of healthcare professionals with specialized training and field experience to help health systems and individual hospitals to design local QI plans.
A key substudy will assess a participant-engagement strategy (digital) of a mobile application utilizing behavioral tools to reinforce health behaviors, including self-monitoring/self-management and medication adherence.
Follow-up will occur via a centralized telephone interview by trained personnel via the DCRI Call Center. At each interview, participants will be asked to report current medications, rehospitalizations, and QOL assessments. Based on participant-reported events, medical billing data for rehospitalizations, emergency department visits, and procedures will be obtained.
Quality of life assessments will include the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQOL five dimensions questionnaire (EQ-5D).
- Conditions
- Heart Failure
- Being tested
- Digital Engagement, Direct Engagement
- Keywords
- Heart Failure, Quality Improvement
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital EngagementOther
Patient engagement to improve self-management/medication adherence
Direct EngagementOther
Health system engagement to improve local QI programs
| Study group | Role | What they receive |
|---|---|---|
| Direct & Digital | Other | Health system engagement to improve local QI programs and patient engagement to improve self-management/medication adherence Receives: Other: Digital Engagement; Other: Direct Engagement |
| Direct & Registry | Other | Health system engagement to improve local QI programs and patient and control Receives: Other: Direct Engagement |
| Digital & Registry | Other | Patient engagement to improve self-management/medication adherence and control Receives: Other: Digital Engagement |
| Registry | No intervention | Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time-to-first HF rehospitalization or death during the 12-months post-discharge
Measured: 12-months after discharge
Improvement in an opportunity-based composite score of adherence to quality metrics for HF.
The opportunity-based composite score will be created to grade the quality of care provided. The numerator will be the number of times that good care is provided; the denominator will be the number of opportunities available. The score will consist of the following quality metrics assessed at the time of hospital discharge and during outpatient follow-up:
- Use of evidence-based specific β-blockers at ≥ 50% target dose
- ACE-I, ARB, or sacubitril/valsartan use at ≥ 50% target dose
- Aldosterone antagonist use
- Anticoagulation use in participants with atrial fibrillation
- In participants with an LVEF ≤ 35%, implantable cardioverter defibrillator placement including cardiac resynchronization therapy placement for participants with sinus rhythm, LBBB, and a QRS ≥ 150 ms
- Attendance at 1 or more of the following: a multidisciplinary HF disease management program, a cardiac rehabilitation program, or HF group educational classes
Measured: Baseline to 12 months post discharge
Secondary outcomes (3)
Improvement in an opportunity-based composite score for adherence to HF discharge quality measures
The opportunity-based composite score will be created to grade the quality of care provided. The numerator will be adherence to medications; the denominator will be the number of opportunities available. The per-opportunity adherence rate will consist of the following quality metrics assessed at the time of hospital discharge:
- ACE-I, ARB, or sacubitril/valsartan prescription at discharge
- ß-blocker prescription at discharge
- Discharge instructions addressing activity level, diet, discharge medications, follow-up appointment, weight monitoring, and how to respond to a change in symptoms
- LVEF assessment
- Smoking cessation counseling
- Medication adherence
Measured: Baseline through study completion, an average of 3 years
If there is a significant positive effect on at least one of the primary endpoints, then participant-level healthcare expenditures
Measured: 6 months and 1 year postdischarge
Cumulative number of primary composite events of death and total (first and recurrent) HF hospitalizations
Measured: Baseline through study completion, an average of 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2017 (estimated)
- Study start21 Apr 2017
- Primary completion31 Dec 2020
- Study completion31 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 5,749 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Collaborators
- Duke Clinical Research Institute
- Responsible party
- Sponsor
- Investigators
- Adam DeVore, MD, MHS, Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03035474
- Sponsor's protocol ID
- Pro00074513
- Acronym
- CONNECT-HF
- Status last verified
- Dec 2020
- First submitted
- 5 Jan 2017
- Last updated
- 25 Jan 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Rao VN, Kaltenbach LA, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Butler J, Allen LA, Lanfear DE, Ariely D, Miller JM, Brodsky MA, Lalonde TA, Lafferty JC, Granger CB, Hernandez AF, Devore AD; Durham, North Carolina; Los Angeles, California; Cleveland, Ohio; Jackson, Misssissippi, Aurora, Colorado; Detroit, Michigan; Ewa Beach, Hawaii; Staten Island, New York. The Association of Digital Health Application Use With Heart Failure Care and Outcomes: Insights From CONNECT-HF. J Card Fail. 2022 Oct;28(10):1487-1496. doi: 10.1016/j.cardfail.2022.07.050. Epub 2022 Jul 26.
PubMed 35905867DeVore AD, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Lewis EF, Butler J, Pina IL, Allen LA, Yancy CW, Cooper LB, Felker GM, Kaltenbach LA, McRae AT, Lanfear DE, Harrison RW, Disch M, Ariely D, Miller JM, Granger CB, Hernandez AF. Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. JAMA. 2021 Jul 27;326(4):314-323. doi: 10.1001/jama.2021.8844.
PubMed 34313687DeVore AD, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Lewis EF, Butler J, Pina IL, Heidenreich PA, Allen LA, Yancy CW, Cooper LB, Felker GM, Kaltenbach LA, McRae AT, Lanfear DE, Harrison RW, Kociol RD, Disch M, Ariely D, Miller JM, Granger CB, Hernandez AF. Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. Am Heart J. 2020 Feb;220:41-50. doi: 10.1016/j.ahj.2019.09.012. Epub 2019 Oct 23.
PubMed 31770656
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure (CONNECT-HF)
- ClinicalTrials.gov ID
- NCT03035474
- Acronym / sponsor ID
- CONNECT-HF / Pro00074513
- Conditions
- Heart Failure
- Keywords
- Heart Failure, Quality Improvement
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5,749 participants (actual)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Collaborators
- Duke Clinical Research Institute
- Study start
- 21 Apr 2017 (actual)
- Primary completion
- 31 Dec 2020 (actual)
- Study completion
- 31 Dec 2020 (actual)
- First posted
- 30 Jan 2017 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CONNECT-HF is a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multifaceted, health system-level quality-improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics.
Detailed description
This trial will be a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multifaceted, health system-level quality-improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics. Outcomes will be assessed following discharge for participants hospitalized with acute HF and reduced left ventricular ejection fraction. All participants in the trial will be consented for follow-up as part of the CONNECT-HF registry on clinical outcomes, medication use, and participant-centered outcomes, including quality-of-life (QOL) assessments will be collected up to 12 months post-discharge at pre-specified intervals (6 weeks and 3, 6, and 12 months).
The health-system QI program will involve site visits and ongoing mentoring from teams of healthcare professionals with specialized training and field experience to help health systems and individual hospitals to design local QI plans.
A key substudy will assess a participant-engagement strategy (digital) of a mobile application utilizing behavioral tools to reinforce health behaviors, including self-monitoring/self-management and medication adherence.
Follow-up will occur via a centralized telephone interview by trained personnel via the DCRI Call Center. At each interview, participants will be asked to report current medications, rehospitalizations, and QOL assessments. Based on participant-reported events, medical billing data for rehospitalizations, emergency department visits, and procedures will be obtained.
Quality of life assessments will include the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQOL five dimensions questionnaire (EQ-5D).
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Direct & Digital | Other | Other: Digital Engagement, Other: Direct EngagementHealth system engagement to improve local QI programs and patient engagement to improve self-management/medication adherence |
| Direct & Registry | Other | Other: Direct EngagementHealth system engagement to improve local QI programs and patient and control |
| Digital & Registry | Other | Other: Digital EngagementPatient engagement to improve self-management/medication adherence and control |
| Registry | No intervention | –Control |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age ≥ 18 years
- Acute HF as a primary cause of hospitalization
- LVEF ≤ 40% based on last local measurement using echocardiography, multigated acquisition scan, computed tomography (CT) scanning, magnetic resonance imaging, or ventricular angiography
- Planned discharge to home or other supported care facility where patients are individually responsible for medication management
Key exclusion criteria (4 listed)
- Prior heart transplant or current/planned left ventricular assistance device
- Chronic kidney disease requiring dialysis
- Terminal illness other than HF, such as malignancy, or with a life expectancy of less than 1 year as determined by the enrolling clinician-investigator
- Unable to participate in longitudinal follow-up, such as plans to move outside the US in the following year
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital EngagementPatient engagement to improve self-management/medication adherence | Other | Digital & Registry, Direct & Digital |
| Direct EngagementHealth system engagement to improve local QI programs | Other | Direct & Digital, Direct & Registry |
Primary outcome
Time-to-first HF rehospitalization or death during the 12-months post-discharge
Time frame: 12-months after discharge
Improvement in an opportunity-based composite score of adherence to quality metrics for HF.
Time frame: Baseline to 12 months post discharge
The opportunity-based composite score will be created to grade the quality of care provided. The numerator will be the number of times that good care is provided; the denominator will be the number of opportunities available. The score will consist of the following quality metrics assessed at the time of hospital discharge and during outpatient follow-up: * Use of evidence-based specific β-blockers at ≥ 50% target dose * ACE-I, ARB, or sacubitril/valsartan use at ≥ 50% target dose * Aldosterone antagonist use * Anticoagulation use in participants with atrial fibrillation * In participants with an LVEF ≤ 35%, implantable cardioverter defibrillator placement including cardiac resynchronization therapy placement for participants with sinus rhythm, LBBB, and a QRS ≥ 150 ms * Attendance at 1 or more of the following: a multidisciplinary HF disease management program, a cardiac rehabilitation program, or HF group educational classes
3 secondary outcomes
Improvement in an opportunity-based composite score for adherence to HF discharge quality measures
Time frame: Baseline through study completion, an average of 3 years
If there is a significant positive effect on at least one of the primary endpoints, then participant-level healthcare expenditures
Time frame: 6 months and 1 year postdischarge
Cumulative number of primary composite events of death and total (first and recurrent) HF hospitalizations
Time frame: Baseline through study completion, an average of 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2021.
- Derived from this study: PubMed 35905867Rao VN, Kaltenbach LA, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Butler J, Allen LA, Lanfear DE, Ariely D, Miller JM, Brodsky MA, Lalonde TA, Lafferty JC, Granger CB, Hernandez AF, Devore AD; Durham, North Carolina; Los Angeles, California; Cleveland, Ohio; Jackson, Misssissippi, Aurora, Colorado; Detroit, Michigan; Ewa Beach, Hawaii; Staten Island, New York. The Association of Digital Health Application Use With Heart Failure Care and Outcomes: Insights From CONNECT-HF. J Card Fail. 2022 Oct;28(10):1487-1496. doi: 10.1016/j.cardfail.2022.07.050. Epub 2022 Jul 26.
- Derived from this study: PubMed 34313687DeVore AD, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Lewis EF, Butler J, Pina IL, Allen LA, Yancy CW, Cooper LB, Felker GM, Kaltenbach LA, McRae AT, Lanfear DE, Harrison RW, Disch M, Ariely D, Miller JM, Granger CB, Hernandez AF. Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. JAMA. 2021 Jul 27;326(4):314-323. doi: 10.1001/jama.2021.8844.
- Derived from this study: PubMed 31770656DeVore AD, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Lewis EF, Butler J, Pina IL, Heidenreich PA, Allen LA, Yancy CW, Cooper LB, Felker GM, Kaltenbach LA, McRae AT, Lanfear DE, Harrison RW, Kociol RD, Disch M, Ariely D, Miller JM, Granger CB, Hernandez AF. Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. Am Heart J. 2020 Feb;220:41-50. doi: 10.1016/j.ahj.2019.09.012. Epub 2019 Oct 23.
- Individual participant dataSharing planned: No
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adam DeVore, MD, MHS principal investigator
Duke University
154 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Digital Engagement and Direct Engagement in people with Heart Failure, run by Duke University at 154 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 154 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time-to-first HF rehospitalization or death during the 12-months post-discharge (time frame: 12-months after discharge). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03035474, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2021.